WELVASTA GOLD 20 combines Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg, bringing antiplatelet protection and intensive lipid-lowering support into one comprehensive cardiovascular formulation. A premium PCD Cardiac-Diabetic portfolio product.
For dual antiplatelet therapy in selected cardiovascular settings.
Yes.
No—only on medical advice.
Use strictly under physician supervision. Report unusual bleeding, black stools, vomiting blood, severe weakness or unexplained muscle pain immediately. Do not discontinue antiplatelet therapy without medical advice.
Bleeding, bruising, gastric discomfort and muscle pain may occur. Rosuvastatin may rarely cause serious muscle injury; antiplatelet therapy increases bleeding risk.
WELVASTA GOLD 20: Aspirin and Clopidogrel inhibit platelet aggregation through complementary pathways, reducing thrombotic risk, while Rosuvastatin lowers LDL cholesterol.
